S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

There Are Weeds In The Garden At Scotts Miracle-Gro

Wednesday, May 4, 2022 | Thomas Hughes
There Are Weeds In The Garden At Scotts Miracle-Gro

Scotts Miracle-Gro Retracts Guidance 

Scotts Miracle-Gro (NYSE: SMG) is experiencing the “cannabis effect” and we should have seen it coming. They got into the cannabis business with the acquisition of Hawthorne way back when there was still some optimism the industry was going to boom and it hasn't. Since then, results in the Hawthorne segment have been tepid and we don’t think they’re going to get any better, not until there is full, national, U.S. legalization anyway and who knows when that will come. Until then, this stock is still a very high-quality dividend grower and one with a sound business. Trading at 13X its earnings it is a value as well and it may be near the bottom. 

Scotts Miracle-Gro Wobbles On Mixed Results 

Scotts Miracle-Gro brought in $1.68 billion in revenue for the quarter which was exactly as expected. The revenue was driven by flat results in the US consumer segment offset by a 44% decline at Hawthorne. Revenue is also down from last year, and the guidance is very weak as well. The bad news is that margins continue to contract despite the company’s efforts to control them. The adjusted gross margin contracted by 110 basis points and there was deleveraging at the operating level as well. The good news is that margin came in above expectation and the company is taking additional steps, beyond pricing, to address the issues and those impacts should be felt very soon. 


“Fortunately, consumer purchases have gained considerable ground in recent weeks. For example, key early-breaking markets in the south are down mid-single digits entering May after being down double digits two weeks earlier. The combination of improved weather, strong retailer promotions through Memorial Day, and favorable comparisons for the balance of the season should be tailwinds for the rest of the year. Still, we now believe the low end of our sales guidance range for U.S. Consumer of plus-or-minus 2 percent from last year’s performance is our most likely outcome,” said Jim Hagedorn, CEO of Scotts Miracle-Gro.

Scotts Miracle-Gro’s Dividend Is Still Growing 

As tepid as the results are, Scotts Miracle-Gro is still a very healthy company and one producing tremendous cash flow. That cash flow is being used to maintain a fortress balance sheet and return capital to shareholders in the form of a dividend. The dividend is a relatively high yield with shares trading near $105, about 2.5%, and there is a positive outlook for growth. The company is paying out less than 30% of its earnings and has a history of increases that spans 12 years. This is part of the reason why the analysts rate the stock a firm Buy but the sentiment is slipping. Barclays is the first to come out with post-earnings commentary and it includes a downgrade from Overweight to Equal Weight and a price target reduction that assumes about 5% of upside for the stock. 

The Technical Outlook: Scotts Miracle-Gro 

Price action in Scotts Miracle-Gro popped in the wake of the earnings report but quickly met resistance below the short-term moving average. The ensuing action is also showing some signs of support, as well, so this may be a bottom in the stock but we don’t think so. The trend is down and guidance has been lowered so there is a real chance for prices to move lower. Assuming the market has already priced in the guidance reduction, price action should confirm support at this level fairly soon. If not, a move to a low could take it back down to the pandemic low before the sell-off is over. 

There Weeds In The Garden At Scotts Miracle-Gro

Should you invest $1,000 in Scotts Miracle-Gro right now?

Before you consider Scotts Miracle-Gro, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scotts Miracle-Gro wasn't on the list.

While Scotts Miracle-Gro currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Scotts Miracle-Gro (SMG)
3.729 of 5 stars
$91.01-0.4%2.90%12.78Buy$164.75
Compare These Stocks  Add These Stocks to My Watchlist 

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.